Nanogen Pegcyte Clinical Study for the Prevention of CIN in Breast-cancer Patients.

A Randomized, Double-blind, Parallel Study Comparing Efficacy and Safety of Pegcyte (Nanogen) and Reference Product Neulastim (Roche) for Prevention of Chemotherapy (Accelerated AC Regimen)Induced Neutropenia in Breast-cancer Patients.

Accelerated AC regimen-Doxorubicin 60 mg/m2,Cyclophosphamide 600 mg/m2 on day 1 & day 14 of each cycle along with G-CSF support for up to 4 cycles, followed by Paclitaxel 175 mg/m2 in the next 4 cycles is the standard clinical practice in Vietnam for breast cancer, this regimen is to facilitate the dose-dense schedule, patients receive every-2-week therapy along with G-CSF support. the accelerated dose-dense schedule improve disease-free and overall survival among women with breast cancer .Primary objective of this study is to compare the efficacy and safety of Nanogen's Pegcyte and Roche's Neulastim for prevention of chemotherapy (Accelerated AC regimen)-induced neutropenia on breast cancer patients. Breast cancer patients scheduled to receive myelosuppressive chemotherapy (AC regimen) will be recruited in this trial. All eligible patients receive single subcutaneous injection of study drugs 24 hours after chemotherapy administration in each cycle for 3 consecutive cycles. Efficacy and safety assessments will be assessed based on the incidence of severe neutropenia in combination of temperature > 38.3℃ or sepsis or life threatening infection and incidence of serious adverse events.

Study Overview

• Status: Completed
• Conditions: Breast Cancer Female
• Intervention / Treatment: Drug: pegcyte; Drug: Neulastim

• Study Type: Interventional
• Enrollment (Actual): 128
• Phase: Phase 3

Contacts and Locations

Study Locations

• Vietnam
  • Hanoi, Vietnam
    • Vietnam National Cancer Institute (Hospital K)

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years to 65 years (Adult, Older Adult)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: Female

Description

Inclusion Criteria:

• Female patients aged between 18 - 65 years.
• Patients with histological confirmed primary invasive breast cancer; stage I, II or III.
• Patients had no prior chemotherapy treatments.
• Patients scheduled to undergo myelosuppressive Doxorubicin and Cyclophosphamide chemotherapy for 04 cycles, and Paclitaxel chemotherapy for the next 04 cycles; patients were available for 14 days of each cycle for the first 03 chemotherapy cycles.
• Patients with baseline ANC ≥ 1.5 x 109/L, PLT ≥ 100 x 109/L, HgB ≥ 9 g/dL, WBC ≥ 3,000/mL and albumin ≥ 3.0 g/dL.
• Performance status as per ECOG (Eastern Cooperative Oncology Group) score 0, 1 or 2.
• Willing to give written and signed informed consent.

Exclusion Criteria:

• Patients with prior exposure of G-CSF or GM-CSF or its pegylated products in clinical development less than 6 months prior to randomization.
• Myelotoxic concomitant treatment such as chloramphenicol, methotrexate, immunomodulating agents, interferons during 10 days before randomization.
• Received systemic antibiotic treatment within 72 hours of chemotherapy.
• Chronic use of corticosteroids, prior bone marrow or stem cell transplant.
• Patients who had an immediate/ concurrent exposure to radiotherapy or surgery (within 4 weeks).
• Severe medical disease: cardiovascular, hepatic, renal, pulmonary…
• Known cases of hematological disease (sickle cell anemia, AML…)
• History of HIV positive, active hepatitis.
• Pregnant and lactating women or patients planning to become pregnant.
• Known allergic reactions to study medications.
• Positive to anti-pegfilgrastim antibody test

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Prevention
• Allocation: Randomized
• Interventional Model: Parallel Assignment
• Masking: Double

Number of Arms

2

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: Pegcyte (Nanogen pegfilgrastim); 6 mg in each cycle	Drug: pegcyte; Eligible patients are scheduled to receive three cycles of chemotherapy every two weeks. During each chemotherapy cycle pegfilgrastim is injected s.c. post chemotherapy application.; Other Names: pegfilgrastim
Active Comparator: Neulastim (Roche pegfilgrastim); 6 mg in each cycle	Drug: Neulastim; Eligible patients are scheduled to receive three cycles of chemotherapy every two weeks. During each chemotherapy cycle pegfilgrastim is injected s.c. post chemotherapy application.; Other Names: pegfilgrastim

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Time Frame
Percentage of patients who developed Febrile neutropenia in cycle 1,2 and 3	0 to 42 days)

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Incidence of grade 4 severe neutropenia		in cycle 1,2 and 3 (0 to 14 , 28 and 42 days)
Incidence of antibiotics use		in cycle 1,2 and 3 (0 to 14 , 28 and 42 days)
Incidence of adverse events		in cycle 1,2 and 3 (0 to 14 , 28 and 42 days)
Changes in laboratory safety parameters	including vital signs	in cycle 1,2 and 3 (0 to 14 , 28 and 42 days)
Presence of antibodies against Pegfilgrastim		at the end of cycle 3 (42 day)

Collaborators and Investigators

• Sponsor: Nanogen Pharmaceutical Biotechnology Joint Stock Company

Study record dates

Study Major Dates

• Study Start (Actual): October 6, 2016
• Primary Completion (Actual): November 6, 2017
• Study Completion (Actual): November 6, 2017

Study Registration Dates

• First Submitted: December 11, 2017
• First Submitted That Met QC Criteria: December 17, 2017
• First Posted (Actual): December 22, 2017

Study Record Updates

• Last Update Posted (Actual): January 2, 2018
• Last Update Submitted That Met QC Criteria: December 28, 2017
• Last Verified: December 1, 2017

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Skin Diseases; Neoplasms; Neoplasms by Site; Breast Diseases; Breast Neoplasms
• Other Study ID Numbers: NNG05

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: Undecided

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No